StockData
Dare Bioscience, Inc. logo

Dare Bioscience, Inc. (DARE) stock

DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$0.58−0.07 (-11.13%)

Close on Nov 16, 2026Market cap $8.93MP/E –Yield –

Dare Bioscience ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Dare Bioscience's ebitda for the twelve months ending Jun 30, 2026 was -$8.98M. For fiscal 2025 it was -$11.92M.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$11.92M–
FY2024Dec 31, 2024-$23.41M–
FY2016Dec 31, 2016-$369.59K–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.40M–
Q1 FY2026Mar 31, 2026-$2.44M–
Q4 FY2025Dec 31, 2025-$936.87K–
Q3 FY2025Sep 30, 2025-$3.20M–
Q2 FY2025Jun 30, 2025-$3.37M–
Q1 FY2025Mar 31, 2025-$4.41M–
Q4 FY2024Dec 31, 2024-$5.38M–
Q3 FY2024Sep 30, 2024-$4.67M–
Q2 FY2024Jun 30, 2024-$7.34M–
Q1 FY2024Mar 31, 2024-$6.01M-9790.5%
Q2 FY2017Jun 30, 2017-$465.62K–
Q1 FY2017Mar 31, 2017-$162.46K–
Q4 FY2016Dec 31, 2016-$122.64K–
Q3 FY2016Sep 30, 2016$62.04K–

More Dare Bioscience figures

See a number that looks wrong?